Who
Justin J. File
CEO, CFO and Secretary
Company insider
Files Form 4 as: CEO, CFO and Secretary, Lite Strategy; Chief Financial Officer, Evofem Biosciences.
In numbers
- Trades disclosed
- 41
- Buys
- 4
- Sells
- 5
- Bought
- $84K
- Sold
- $132K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 17 Jan 2018
- Last trade
- 12 Feb 2026
- Last filed
- 12 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Feb 2026filed 12 Feb 2026 | LITS Lite Strategyoption or derivative · Biotechnology | SEC FORM 4 Code A | —455,000 | filing |
| 12 Feb 2026filed 12 Feb 2026 | LITS Lite Strategyoption or derivative · Biotechnology | SEC FORM 4 Code A | —455,000 | filing |
| 14 Nov 2025filed 20 Nov 2025 | LITS Lite Strategyoption or derivative · Biotechnology | SEC FORM 4 Code A | —180,000 | filing |
| 14 Nov 2025filed 18 Nov 2025 | LITS Lite Strategyoption or derivative · Biotechnology | SEC FORM 4 Code A | —635,000 | filing |
| 15 Jul 2025filed 17 Jul 2025 | LITS Lite Strategyoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 31 Dec 2022filed 8 May 2023 | Evofem BiosciencesBiotechnology | SEC FORM 4 Code D | —30,000 at $0.00 | filing |
| 18 Feb 2022filed 23 Feb 2022 | Evofem Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —450,000 at $0.00 | filing |
| 18 Feb 2022filed 23 Feb 2022 | Evofem BiosciencesBiotechnology | SEC FORM 4 Code A | —450,000 at $0.00 | filing |
| 31 Dec 2021filed 4 Jan 2022 | Evofem BiosciencesBiotechnology | SEC FORM 4 Code D | —120,000 at $0.00 | filing |
| 20 Dec 2021filed 20 Dec 2021 | Evofem BiosciencesBiotechnology | SEC FORM 4 Bought | $15K40,594 at $0.37 | filing |
| 10 Jun 2021filed 10 Jun 2021 | Evofem BiosciencesBiotechnology | SEC FORM 4 Bought | $25K24,500 at $1.03 | filing |
| 20 May 2021filed 21 May 2021 | Evofem BiosciencesBiotechnology | SEC FORM 4 Code F | $36K42,280 at $0.86 | filing |
| 3 Feb 2021filed 3 Feb 2021 | Evofem Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 3 Feb 2021filed 3 Feb 2021 | Evofem BiosciencesBiotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 17 Nov 2020filed 18 Nov 2020 | Evofem BiosciencesBiotechnology | SEC FORM 4 Bought | $17K7,760 at $2.17 | filing |
| 12 Jun 2020filed 15 Jun 2020 | Evofem BiosciencesBiotechnology | SEC FORM 4 Bought | $27K8,500 at $3.14 | filing |
| 5 Jun 2020filed 8 Jun 2020 | Evofem BiosciencesBiotechnology | SEC FORM 4 Code F | $142K42,810 at $3.31 | filing |
| 22 May 2020filed 26 May 2020 | Evofem BiosciencesBiotechnology | SEC FORM 4 Code F | $211K42,262 at $4.99 | filing |
| 6 May 2020filed 8 May 2020 | Evofem BiosciencesBiotechnology | SEC FORM 4 Code F | $44K8,420 at $5.24 | filing |
| 5 Feb 2020filed 7 Feb 2020 | Evofem Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.